{
    "symbol": "RVNC",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-09 23:20:26",
    "content": "  During this conference call, management will make forward-looking statements, including statements related to the regulatory process and potential approval for DaxibotulinumtoxinA for Injection  in glabellar lines and in therapeutic indication, potential indications for RHA Redensity to the fact of RHA questions and open platform, consumer preferences, the benefits to us, practices and patients of our products and services, our financial performance, 2022 guidance, expected cash runway, strategic priorities and capital allocation plans, our market and revenue opportunity, our potential growth and our business strategy, planned operations and commercialization plans."
}